Morgan Stanley Boosts Amgen (NASDAQ:AMGN) Price Target to $326.00

Amgen (NASDAQ:AMGN) had its price target increased by analysts at Morgan Stanley from $309.00 to $326.00 in a report released on Friday, MarketBeat.com reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Morgan Stanley’s target price suggests a potential downside of 7.10% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Citigroup lifted their price target on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft lifted their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Finally, Piper Sandler lifted their price target on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $355.84.

Amgen Trading Down 1.3%

Shares of Amgen stock opened at $350.92 on Friday. The firm has a market cap of $189.39 billion, a price-to-earnings ratio of 24.66, a PEG ratio of 3.48 and a beta of 0.47. The business has a 50-day moving average price of $363.87 and a 200-day moving average price of $335.08. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen will post 20.62 EPS for the current fiscal year.

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp lifted its stake in Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors lifted its stake in Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Capital International Investors lifted its stake in Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen’s lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.